ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,033,569 | -26.5% | 1,266,601 | -2.4% | 0.01% | -22.2% |
| Q2 2023 | $46,296,772 | +38.1% | 1,298,283 | -1.6% | 0.01% | +28.6% |
| Q1 2023 | $33,527,796 | -35.6% | 1,319,992 | +2.8% | 0.01% | -36.4% |
| Q4 2022 | $52,070,928 | +23.2% | 1,283,800 | +0.4% | 0.01% | +10.0% |
| Q3 2022 | $42,273,000 | -7.4% | 1,279,056 | -1.3% | 0.01% | 0.0% |
| Q2 2022 | $45,637,000 | -28.4% | 1,296,143 | -6.4% | 0.01% | -9.1% |
| Q1 2022 | $63,715,000 | -32.4% | 1,385,394 | -2.6% | 0.01% | -26.7% |
| Q4 2021 | $94,288,000 | +4.6% | 1,422,149 | -1.5% | 0.02% | -6.2% |
| Q3 2021 | $90,145,000 | -27.0% | 1,443,951 | -3.2% | 0.02% | -27.3% |
| Q2 2021 | $123,488,000 | +20.5% | 1,491,038 | -3.6% | 0.02% | +15.8% |
| Q1 2021 | $102,521,000 | -14.3% | 1,546,068 | -0.8% | 0.02% | -17.4% |
| Q4 2020 | $119,578,000 | +74.1% | 1,558,425 | -2.3% | 0.02% | +53.3% |
| Q3 2020 | $68,695,000 | -5.6% | 1,595,308 | -5.3% | 0.02% | -11.8% |
| Q2 2020 | $72,765,000 | +56.2% | 1,684,762 | +4.1% | 0.02% | +30.8% |
| Q1 2020 | $46,584,000 | -52.7% | 1,619,185 | +4.3% | 0.01% | -40.9% |
| Q4 2019 | $98,489,000 | +172.1% | 1,552,707 | +20.9% | 0.02% | +144.4% |
| Q3 2019 | $36,193,000 | +8.6% | 1,284,336 | +2.2% | 0.01% | +12.5% |
| Q2 2019 | $33,315,000 | +51.8% | 1,257,200 | +5.1% | 0.01% | +60.0% |
| Q1 2019 | $21,948,000 | +62.4% | 1,196,067 | +9.9% | 0.01% | +25.0% |
| Q4 2018 | $13,517,000 | -36.4% | 1,088,312 | -1.9% | 0.00% | -20.0% |
| Q3 2018 | $21,265,000 | +47.0% | 1,109,264 | +4.3% | 0.01% | +25.0% |
| Q2 2018 | $14,464,000 | +805.7% | 1,063,499 | +380.1% | 0.00% | – |
| Q1 2018 | $1,597,000 | +120.6% | 221,517 | +12.7% | 0.00% | – |
| Q4 2017 | $724,000 | -14.2% | 196,585 | +0.8% | 0.00% | – |
| Q3 2017 | $844,000 | +133.8% | 194,974 | -12.4% | 0.00% | – |
| Q2 2017 | $361,000 | -78.1% | 222,692 | -75.0% | 0.00% | – |
| Q1 2017 | $1,646,000 | +29.2% | 889,977 | +8.2% | 0.00% | – |
| Q4 2016 | $1,274,000 | -75.0% | 822,261 | +18.4% | 0.00% | -100.0% |
| Q3 2016 | $5,104,000 | +40.0% | 694,576 | +1.4% | 0.00% | +100.0% |
| Q2 2016 | $3,645,000 | – | 685,185 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |